Luseogliflozin hydrate

Luseogliflozin hydrate is a medication for managing type 2 diabetes mellitus (T2DM) by improving glycemic control. As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, it works by helping the kidneys excrete excess glucose from the blood into the urine. It can also lead to other benefits including lowering body weight, blood pressure, and triglycerides, particularly in patients with higher BMI. It is grouped under the following drug class(es): Hypoglycemics and SGLT2 inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Luseogliflozin hemihydrate and Tafolec. Its PubChem CID is 56928196.

CAS No 1152425-66-5
Molecular Formula C23H32O7S
Molecular Weight 452.60 g/mol
Synonyms (2S,3R,4R,5S,6R)-2-[5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl]-6-(hydroxymethyl)thiane-3,4,5-triol;hydrate

Frequently Asked Questions